Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma

Summary

This research study is studying a drug as a possible treatment for High Grade Meningioma. The drug involved in this study is an immunotherapy drug called pembrolizumab

Timeline

Start

2017-11-07

Primary completion

2021-09-18

Completion

2026-12-31

Outcome

Met primary endpoint

paper Our study has met its primary endpoint PMID 35289329 ↗

Publications

• Brastianos PK, Kim AE, Giobbie-Hurder A, Lee EQ, Wang N, Eichler AF, Chukwueke U, Forst DA, Arrillaga-Romany IC, Dietrich J, Corbin Z, Moliterno J, Baehring J, White M, Lou KW, Larson J, de Sauvage MA, Evancic K, Mora J, Nayyar N, Loeffler J, Oh K, Shih HA, Curry WT, Cahill DP, Barker FG, Gerstner ER, Santagata S. Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. Nat Commun. 2022 Mar 14;13(1):1325. doi: 10.1038/s41467-022-29052-7.

Drugs

Indications